The indolocarbazole derivative LCS-1269 has a multitarget mechanism of action on tumors and blocks vasculogenic mimicry. The hydrophobic character of LCS-1269 hampers the development of an injectable dosage form (IDF), the need for which was determined in series of in vitro and in vivo biological experiments. The purpose of this study was to select an excipient composition for creating a model IDF of LCS-1269 with high antitumor activity and low toxicity and to develop the technology for LCS-1269 IDF production. Acomposition of a model IDF of LCS-1269 including EtOH (95%), Kollidon 17 PF, and polysorbate 80 and the technology for obtaining a true solution were developed during preliminary experimental studies. The selected model was lyophilized to exclude EtOH from the composition and to increase the shelf life of the compound.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
I. Gulyakin, A. Lantsova, L. Nikolaeva, et al., Int. J. App. Pharm., 13(4), 102 – 105 (2021); doi: https://doi.org/10.22159/ijap_2021v13i4.41371.
M. Dmitrieva, A. Kolpaksidi, O. Orlova, et al., Int. J. App. Pharm., 13(6), 232 – 235 (2021); doi: https://doi.org/10.22159/ijap_2021v13i6.42685.
L. V. Ektova, O. V. Goryunova, V. A. Eremina, et al., Khim.-farm. Zh., 53(7), 13 – 17 (2019); Pharm. Chem. J., 53(7), 604 – 609 (2019); doi: https://doi.org/10.1007/s11094-019-02046-4.
K. Kawakami, N. Oda, K. Miyoshi, et al., Eur. J. Pharm. Sci., 28, 7 – 14 (2006); doi: https://doi.org/10.1016/j.ejps.2005.11.012.
Z. Shprakh, A. Budko, D. Kozin, et al., Pharmacia, 68(2), 427 – 431 (2021); doi: 10.3897 / pharmacia.68.e63457.
D. A. Kozin, Z. C. Shprakh, A. P. Budko, et al., Med.-farm. Zh. Pul’s, 25(1), 78 – 82 (2023); doi: https://doi.org/10.26787/nydha-2686-6838-2023-25-1-78-82.
A. Lantsova, I. Golubeva, L. Borisova, et al., BMC Complementary Med. Ther., 21, 117 (2021); doi: https://doi.org/10.1186/s12906-021-03294-2.
E. V. Sanarova, A. V. Lantsova, and N. A. Oborotova, Russ. J. Biopharm., 7(3), 3 – 9 (2015).
A. V. Lantsova, L. L. Nikolaeva, et al., RU Pat. 2,786,727 C1, Dec. 26, 2022; https: //www.elibrary.ru/item.asp?id=50007438.
E. V. Ignat?eva, I. V. Yartseva, Z. S. Shprakh, et al., Ross. Bioterapevticheskii Zh., 21(3), 61 – 71 (2022); doi: https://doi.org/10.17650/1726-9784-2022-21-3-61-71.
A. Vyas, S. Saraf, and S. Saraf, J. Inclusion Phenom. Macrocyclic Chem., 62, 23 – 42 (2008); doi: https://doi.org/10.1007/s10847-008-9456-y.
I. D. Gulyakin, N. A. Oborotova, and V. M. Pechennikov, Khim.- farm. Zh., 48(3), 46 – 50 (2014); Pharm. Chem. J., 48(3), 209 – 213 (2014); doi: https://doi.org/10.1007/s11094-014-1078-7.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 57, No. 6, pp. 42 – 46, June, 2023
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nikolaeva, L.L., Lantsova, A.V., Sanarova, E.V. et al. Development of the Composition and Technology for Obtaining a Model of an Injection Form of an Indolocarbazole Derivative. Pharm Chem J 57, 874–878 (2023). https://doi.org/10.1007/s11094-023-02962-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-023-02962-6